secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001213900-24-054003
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra advances new RASP modulators ADX-743, ADX-248, ADX-631; pediatric ADX-629 top-line results expected 2025
--------------------------------------------------------------------------------

- ADX-629 advanced to pediatric cohort in Sjögren-Larsson Syndrome Phase 2; top-line results from ~5 patients expected 2025.
- Novel RASP modulator ADX-743 entered IND-enabling studies for obesity; IND submission planned 2025.
- ADX-248 selected over ADX-246 for Phase 1/2 in atopic dermatitis; Phase 1 to start H2 2024.
- ADX-631 initiated preclinical testing in retinal disease; IND submission for dry AMD/geographic atrophy expected H1 2025.
- Investor roundtable webcast June 20, 2024 at 8:00 am ET to discuss these pipeline updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/0001213900-24-054003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024054003/ea0208142-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-054003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer